{"id":64570,"date":"2026-05-08T20:00:02","date_gmt":"2026-05-08T12:00:02","guid":{"rendered":"https:\/\/flcube.com\/?p=64570"},"modified":"2026-05-08T20:00:03","modified_gmt":"2026-05-08T12:00:03","slug":"huadong-medicines-asthma-drug-cxg87-receives-nmpa-filing-acceptance-following-successful-phase-iii-trial-against-symbicort","status":"publish","type":"post","link":"https:\/\/flcube.com\/?p=64570","title":{"rendered":"Huadong Medicine&#8217;s Asthma Drug CXG87 Receives NMPA Filing Acceptance Following Successful Phase III Trial Against Symbicort"},"content":{"rendered":"\n<p><strong>Huadong Medicine Co., Ltd.<\/strong> (<a href=\"https:\/\/www.google.com\/finance\/quote\/000963:SHE\">SHE: 000963<\/a>) announced that the <strong>National Medical Products Administration (NMPA)<\/strong> has accepted for review its <strong>market filing for CXG87<\/strong>, a <strong>budesonide and formoterol fumarate powder for inhalation (IV), hard capsule<\/strong> developed for <strong>asthma treatment to achieve overall disease control<\/strong>. The <strong>Category 2.2 modified drug<\/strong>, originally developed by <strong>Chance Pharmaceuticals<\/strong>, demonstrated <strong>non-inferiority to AstraZeneca&#8217;s Symbicort Turbuhaler<\/strong> in Phase III trials, positioning Huadong Medicine to capture significant share in China&#8217;s competitive respiratory therapeutics market.<\/p>\n\n\n\n<h2 class=\"wp-block-heading\" id=\"h-regulatory-milestone-overview\">Regulatory Milestone Overview<\/h2>\n\n\n\n<figure class=\"wp-block-table\"><table class=\"has-fixed-layout\"><thead><tr><th>Parameter<\/th><th>Detail<\/th><\/tr><\/thead><tbody><tr><td><strong>Drug Name<\/strong><\/td><td>CXG87 (budesonide\/formoterol fumarate powder for inhalation)<\/td><\/tr><tr><td><strong>Classification<\/strong><\/td><td>Category 2.2 modified drug (China NMPA classification)<\/td><\/tr><tr><td><strong>Indication<\/strong><\/td><td>Treatment of asthma for overall disease control<\/td><\/tr><tr><td><strong>Regulatory Status<\/strong><\/td><td>NMPA market filing accepted for review<\/td><\/tr><tr><td><strong>Development Origin<\/strong><\/td><td>Chance Pharmaceuticals (licensed to Huadong Medicine)<\/td><\/tr><tr><td><strong>Commercial Rights<\/strong><\/td><td>Exclusive mainland China rights held by Huadong Medicine as MAH<\/td><\/tr><\/tbody><\/table><\/figure>\n\n\n\n<h2 class=\"wp-block-heading\" id=\"h-clinical-development-success\">Clinical Development Success<\/h2>\n\n\n\n<h3 class=\"wp-block-heading\" id=\"h-phase-iii-trial-results\">Phase III Trial Results<\/h3>\n\n\n\n<ul class=\"wp-block-list\">\n<li><strong>Primary Endpoint<\/strong>: Met after 42 days of treatment with <strong>statistical non-inferiority to Symbicort Turbuhaler<\/strong><\/li>\n\n\n\n<li><strong>Lung Function<\/strong>: Clear improvements in pulmonary function parameters vs. baseline<\/li>\n\n\n\n<li><strong>Symptom Control<\/strong>: Favorable trends in asthma symptom relief and quality of life measures<\/li>\n\n\n\n<li><strong>Exacerbation Reduction<\/strong>: Decreased frequency of acute asthma exacerbations compared to control<\/li>\n\n\n\n<li><strong>Safety Profile<\/strong>: Comparable to AstraZeneca&#8217;s reference product with no new safety signals identified<\/li>\n<\/ul>\n\n\n\n<h3 class=\"wp-block-heading\" id=\"h-product-differentiation\">Product Differentiation<\/h3>\n\n\n\n<ul class=\"wp-block-list\">\n<li><strong>Delivery System<\/strong>: Hard capsule powder for inhalation format offering patient-friendly administration<\/li>\n\n\n\n<li><strong>Dosing Convenience<\/strong>: Fixed-dose combination eliminating need for separate ICS\/LABA prescriptions<\/li>\n\n\n\n<li><strong>Manufacturing Innovation<\/strong>: Proprietary formulation ensuring consistent drug delivery and stability<\/li>\n<\/ul>\n\n\n\n<h2 class=\"wp-block-heading\" id=\"h-strategic-partnership-framework\">Strategic Partnership Framework<\/h2>\n\n\n\n<h3 class=\"wp-block-heading\" id=\"h-licensing-agreement-with-chance-pharmaceuticals\">Licensing Agreement with Chance Pharmaceuticals<\/h3>\n\n\n\n<ul class=\"wp-block-list\">\n<li><strong>Deal Structure<\/strong>: October 2025 agreement granting exclusive mainland China rights<\/li>\n\n\n\n<li><strong>Scope<\/strong>: Development, regulatory filing, manufacturing, supply, and commercial promotion<\/li>\n\n\n\n<li><strong>MAH Status<\/strong>: Huadong Medicine serves as Marketing Authorization Holder<\/li>\n\n\n\n<li><strong>Commercial Exclusivity<\/strong>: Sole rights for mainland China market<\/li>\n<\/ul>\n\n\n\n<h3 class=\"wp-block-heading\" id=\"h-business-rationale\">Business Rationale<\/h3>\n\n\n\n<ul class=\"wp-block-list\">\n<li><strong>Portfolio Expansion<\/strong>: Strengthens Huadong&#8217;s respiratory therapeutic franchise<\/li>\n\n\n\n<li><strong>Market Opportunity<\/strong>: Addresses China&#8217;s substantial asthma patient population (estimated 30+ million)<\/li>\n\n\n\n<li><strong>Competitive Positioning<\/strong>: Direct competitor to established global brands including Symbicort and Seretide<\/li>\n\n\n\n<li><strong>Pricing Strategy<\/strong>: Expected premium pricing with potential NRDL inclusion pathway<\/li>\n<\/ul>\n\n\n\n<h2 class=\"wp-block-heading\" id=\"h-market-opportunity-assessment\">Market Opportunity Assessment<\/h2>\n\n\n\n<h3 class=\"wp-block-heading\" id=\"h-china-asthma-therapeutics-landscape\">China Asthma Therapeutics Landscape<\/h3>\n\n\n\n<ul class=\"wp-block-list\">\n<li><strong>Patient Burden<\/strong>: Over 30 million asthma patients with significant unmet treatment needs<\/li>\n\n\n\n<li><strong>Current Standard<\/strong>: Combination ICS\/LABA therapies dominate maintenance treatment<\/li>\n\n\n\n<li><strong>Market Size<\/strong>: China respiratory drugs market valued at <strong>\u00a525 billion ($3.5 billion)<\/strong> annually<\/li>\n\n\n\n<li><strong>Growth Drivers<\/strong>: Increasing diagnosis rates, improved treatment guidelines, expanding insurance coverage<\/li>\n<\/ul>\n\n\n\n<h3 class=\"wp-block-heading\" id=\"h-competitive-dynamics\">Competitive Dynamics<\/h3>\n\n\n\n<ul class=\"wp-block-list\">\n<li><strong>Global Incumbents<\/strong>: AstraZeneca (Symbicort), GSK (Seretide), Novartis (Symbicort generics)<\/li>\n\n\n\n<li><strong>Domestic Competition<\/strong>: Limited local players with comparable clinical data and manufacturing capability<\/li>\n\n\n\n<li><strong>Regulatory Advantage<\/strong>: Category 2.2 designation provides data exclusivity and market protection<\/li>\n\n\n\n<li><strong>Reimbursement Potential<\/strong>: Strong candidate for National Reimbursement Drug List (NRDL) inclusion<\/li>\n<\/ul>\n\n\n\n<h2 class=\"wp-block-heading\" id=\"h-commercial-strategy-and-financial-impact\">Commercial Strategy and Financial Impact<\/h2>\n\n\n\n<h3 class=\"wp-block-heading\" id=\"h-market-access-approach\">Market Access Approach<\/h3>\n\n\n\n<ul class=\"wp-block-list\">\n<li><strong>Hospital Penetration<\/strong>: Leveraging Huadong&#8217;s established hospital sales force and relationships<\/li>\n\n\n\n<li><strong>Physician Education<\/strong>: Comprehensive training programs on proper inhalation technique and disease management<\/li>\n\n\n\n<li><strong>Patient Support<\/strong>: Adherence programs and monitoring tools to optimize treatment outcomes<\/li>\n\n\n\n<li><strong>Pricing Positioning<\/strong>: Premium pricing justified by clinical equivalence to global standard<\/li>\n<\/ul>\n\n\n\n<h3 class=\"wp-block-heading\" id=\"h-revenue-projections\">Revenue Projections<\/h3>\n\n\n\n<ul class=\"wp-block-list\">\n<li><strong>Peak Sales Estimate<\/strong>: Analysts project <strong>\u00a5800 million\u20131.2 billion<\/strong> ($110\u2013170 million) annual revenue at peak adoption<\/li>\n\n\n\n<li><strong>Market Share Target<\/strong>: 15\u201320% of China&#8217;s branded ICS\/LABA combination segment within three years<\/li>\n\n\n\n<li><strong>Contribution Margin<\/strong>: High-margin product supporting overall profitability improvement<\/li>\n<\/ul>\n\n\n\n<h3 class=\"wp-block-heading\" id=\"h-manufacturing-and-supply-chain\">Manufacturing and Supply Chain<\/h3>\n\n\n\n<ul class=\"wp-block-list\">\n<li><strong>Production Capacity<\/strong>: Existing GMP facilities capable of commercial-scale manufacturing<\/li>\n\n\n\n<li><strong>Quality Assurance<\/strong>: Stringent quality control ensuring batch-to-batch consistency<\/li>\n\n\n\n<li><strong>Supply Security<\/strong>: Vertical integration from API to finished product ensuring reliability<\/li>\n<\/ul>\n\n\n\n<h2 class=\"wp-block-heading\" id=\"h-investment-implications\">Investment Implications<\/h2>\n\n\n\n<ul class=\"wp-block-list\">\n<li><strong>Stock Performance<\/strong>: SHE: 000963 closed at \u00a532.45 on May 7, 2026; respiratory franchise expansion viewed positively<\/li>\n\n\n\n<li><strong>Pipeline Valuation<\/strong>: CXG87 represents significant near-term commercial catalyst<\/li>\n\n\n\n<li><strong>Strategic Significance<\/strong>: Demonstrates successful external innovation sourcing and development execution<\/li>\n\n\n\n<li><strong>Long-term Vision<\/strong>: Foundation for broader respiratory disease portfolio expansion<\/li>\n<\/ul>\n\n\n\n<p><strong>Forward-Looking Statements<\/strong><br>This brief contains forward-looking statements regarding CXG87&#8217;s regulatory review, commercial projections, and market opportunity. Actual results may vary due to regulatory decisions, competitive dynamics, and market access negotiations.<a href=\"https:\/\/flcube.com\/\">-Fineline Info &amp; Tech<\/a><\/p>\n","protected":false},"excerpt":{"rendered":"<p>Huadong Medicine Co., Ltd. (SHE: 000963) announced that the National Medical Products Administration (NMPA) has&#8230;<\/p>\n","protected":false},"author":1,"featured_media":0,"comment_status":"open","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"googlesitekit_rrm_CAownpewDA:productID":"","_jetpack_memberships_contains_paid_content":false,"footnotes":"","jetpack_publicize_message":"","jetpack_publicize_feature_enabled":true,"jetpack_social_post_already_shared":true,"jetpack_social_options":{"image_generator_settings":{"template":"highway","default_image_id":0,"font":"","enabled":false},"version":2}},"categories":[7,11],"tags":[114,38,887],"class_list":["post-64570","post","type-post","status-publish","format-standard","hentry","category-company","category-drug","tag-huadong-medicine","tag-market-approval-filings","tag-she-000963"],"yoast_head":"<!-- This site is optimized with the Yoast SEO Premium plugin v23.6 (Yoast SEO v27.5) - https:\/\/yoast.com\/product\/yoast-seo-premium-wordpress\/ -->\n<title>Huadong Medicine&#039;s Asthma Drug CXG87 Receives NMPA Filing Acceptance Following Successful Phase III Trial Against Symbicort - Insight, China&#039;s Pharmaceutical Industry<\/title>\n<meta name=\"description\" content=\"Navigate the complexities of China\u2019s pharmaceutical industry with precision and clarity. FLCUBE delivers reliable data, news, and intelligence to broaden your horizons and sharpen your decision-making. Stay informed, stay ahead with FLCUBE.COM\" \/>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/flcube.com\/?p=64570\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Huadong Medicine&#039;s Asthma Drug CXG87 Receives NMPA Filing Acceptance Following Successful Phase III Trial Against Symbicort\" \/>\n<meta property=\"og:description\" content=\"Navigate the complexities of China\u2019s pharmaceutical industry with precision and clarity. FLCUBE delivers reliable data, news, and intelligence to broaden your horizons and sharpen your decision-making. Stay informed, stay ahead with FLCUBE.COM\" \/>\n<meta property=\"og:url\" content=\"https:\/\/flcube.com\/?p=64570\" \/>\n<meta property=\"og:site_name\" content=\"Insight, China&#039;s Pharmaceutical Industry\" \/>\n<meta property=\"article:publisher\" content=\"https:\/\/www.facebook.com\/profile.php?id=61566606313834\" \/>\n<meta property=\"article:published_time\" content=\"2026-05-08T12:00:02+00:00\" \/>\n<meta property=\"article:modified_time\" content=\"2026-05-08T12:00:03+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/flcube.com\/wp-content\/uploads\/2024\/11\/Fineline-info-tech-scaled.jpg\" \/>\n\t<meta property=\"og:image:width\" content=\"2560\" \/>\n\t<meta property=\"og:image:height\" content=\"1894\" \/>\n\t<meta property=\"og:image:type\" content=\"image\/jpeg\" \/>\n<meta name=\"author\" content=\"Fineline Cube\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Fineline Cube\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"3 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=64570#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=64570\"},\"author\":{\"name\":\"Fineline Cube\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/person\\\/19ad11870d326204db8524d3c3c5e66a\"},\"headline\":\"Huadong Medicine&#8217;s Asthma Drug CXG87 Receives NMPA Filing Acceptance Following Successful Phase III Trial Against Symbicort\",\"datePublished\":\"2026-05-08T12:00:02+00:00\",\"dateModified\":\"2026-05-08T12:00:03+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=64570\"},\"wordCount\":629,\"commentCount\":0,\"publisher\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\"},\"keywords\":[\"Huadong Medicine\",\"Market approval filings\",\"SHE: 000963\"],\"articleSection\":[\"Company\",\"Drug\"],\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"CommentAction\",\"name\":\"Comment\",\"target\":[\"https:\\\/\\\/flcube.com\\\/?p=64570#respond\"]}],\"copyrightYear\":\"2026\",\"copyrightHolder\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\"}},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=64570\",\"url\":\"https:\\\/\\\/flcube.com\\\/?p=64570\",\"name\":\"Huadong Medicine's Asthma Drug CXG87 Receives NMPA Filing Acceptance Following Successful Phase III Trial Against Symbicort - Insight, China&#039;s Pharmaceutical Industry\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#website\"},\"datePublished\":\"2026-05-08T12:00:02+00:00\",\"dateModified\":\"2026-05-08T12:00:03+00:00\",\"description\":\"Navigate the complexities of China\u2019s pharmaceutical industry with precision and clarity. FLCUBE delivers reliable data, news, and intelligence to broaden your horizons and sharpen your decision-making. Stay informed, stay ahead with FLCUBE.COM\",\"breadcrumb\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=64570#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/flcube.com\\\/?p=64570\"]}]},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=64570#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\\\/\\\/flcube.com\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Huadong Medicine&#8217;s Asthma Drug CXG87 Receives NMPA Filing Acceptance Following Successful Phase III Trial Against Symbicort\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#website\",\"url\":\"https:\\\/\\\/flcube.com\\\/\",\"name\":\"Insight, China's Pharmaceutical Industry\",\"description\":\"Fineline Insights, Pharma Clarity\",\"publisher\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\"},\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/flcube.com\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Organization\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\",\"name\":\"Fineline Infomation and Technology\",\"alternateName\":\"Fineline Info & Tech\",\"url\":\"https:\\\/\\\/flcube.com\\\/\",\"logo\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/logo\\\/image\\\/\",\"url\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2024\\\/11\\\/Fineline-info-tech-scaled.jpg\",\"contentUrl\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2024\\\/11\\\/Fineline-info-tech-scaled.jpg\",\"width\":2560,\"height\":1894,\"caption\":\"Fineline Infomation and Technology\"},\"image\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/logo\\\/image\\\/\"},\"sameAs\":[\"https:\\\/\\\/www.facebook.com\\\/profile.php?id=61566606313834\"]},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/person\\\/19ad11870d326204db8524d3c3c5e66a\",\"name\":\"Fineline Cube\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g\",\"url\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g\",\"contentUrl\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g\",\"caption\":\"Fineline Cube\"},\"sameAs\":[\"https:\\\/\\\/flcube.com\"],\"url\":\"https:\\\/\\\/flcube.com\\\/?author=1\"}]}<\/script>\n<!-- \/ Yoast SEO Premium plugin. -->","yoast_head_json":{"title":"Huadong Medicine's Asthma Drug CXG87 Receives NMPA Filing Acceptance Following Successful Phase III Trial Against Symbicort - Insight, China&#039;s Pharmaceutical Industry","description":"Navigate the complexities of China\u2019s pharmaceutical industry with precision and clarity. FLCUBE delivers reliable data, news, and intelligence to broaden your horizons and sharpen your decision-making. Stay informed, stay ahead with FLCUBE.COM","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/flcube.com\/?p=64570","og_locale":"en_US","og_type":"article","og_title":"Huadong Medicine's Asthma Drug CXG87 Receives NMPA Filing Acceptance Following Successful Phase III Trial Against Symbicort","og_description":"Navigate the complexities of China\u2019s pharmaceutical industry with precision and clarity. FLCUBE delivers reliable data, news, and intelligence to broaden your horizons and sharpen your decision-making. Stay informed, stay ahead with FLCUBE.COM","og_url":"https:\/\/flcube.com\/?p=64570","og_site_name":"Insight, China&#039;s Pharmaceutical Industry","article_publisher":"https:\/\/www.facebook.com\/profile.php?id=61566606313834","article_published_time":"2026-05-08T12:00:02+00:00","article_modified_time":"2026-05-08T12:00:03+00:00","og_image":[{"width":2560,"height":1894,"url":"https:\/\/flcube.com\/wp-content\/uploads\/2024\/11\/Fineline-info-tech-scaled.jpg","type":"image\/jpeg"}],"author":"Fineline Cube","twitter_card":"summary_large_image","twitter_misc":{"Written by":"Fineline Cube","Est. reading time":"3 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/flcube.com\/?p=64570#article","isPartOf":{"@id":"https:\/\/flcube.com\/?p=64570"},"author":{"name":"Fineline Cube","@id":"https:\/\/flcube.com\/#\/schema\/person\/19ad11870d326204db8524d3c3c5e66a"},"headline":"Huadong Medicine&#8217;s Asthma Drug CXG87 Receives NMPA Filing Acceptance Following Successful Phase III Trial Against Symbicort","datePublished":"2026-05-08T12:00:02+00:00","dateModified":"2026-05-08T12:00:03+00:00","mainEntityOfPage":{"@id":"https:\/\/flcube.com\/?p=64570"},"wordCount":629,"commentCount":0,"publisher":{"@id":"https:\/\/flcube.com\/#organization"},"keywords":["Huadong Medicine","Market approval filings","SHE: 000963"],"articleSection":["Company","Drug"],"inLanguage":"en-US","potentialAction":[{"@type":"CommentAction","name":"Comment","target":["https:\/\/flcube.com\/?p=64570#respond"]}],"copyrightYear":"2026","copyrightHolder":{"@id":"https:\/\/flcube.com\/#organization"}},{"@type":"WebPage","@id":"https:\/\/flcube.com\/?p=64570","url":"https:\/\/flcube.com\/?p=64570","name":"Huadong Medicine's Asthma Drug CXG87 Receives NMPA Filing Acceptance Following Successful Phase III Trial Against Symbicort - Insight, China&#039;s Pharmaceutical Industry","isPartOf":{"@id":"https:\/\/flcube.com\/#website"},"datePublished":"2026-05-08T12:00:02+00:00","dateModified":"2026-05-08T12:00:03+00:00","description":"Navigate the complexities of China\u2019s pharmaceutical industry with precision and clarity. FLCUBE delivers reliable data, news, and intelligence to broaden your horizons and sharpen your decision-making. Stay informed, stay ahead with FLCUBE.COM","breadcrumb":{"@id":"https:\/\/flcube.com\/?p=64570#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/flcube.com\/?p=64570"]}]},{"@type":"BreadcrumbList","@id":"https:\/\/flcube.com\/?p=64570#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/flcube.com\/"},{"@type":"ListItem","position":2,"name":"Huadong Medicine&#8217;s Asthma Drug CXG87 Receives NMPA Filing Acceptance Following Successful Phase III Trial Against Symbicort"}]},{"@type":"WebSite","@id":"https:\/\/flcube.com\/#website","url":"https:\/\/flcube.com\/","name":"Insight, China's Pharmaceutical Industry","description":"Fineline Insights, Pharma Clarity","publisher":{"@id":"https:\/\/flcube.com\/#organization"},"potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/flcube.com\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Organization","@id":"https:\/\/flcube.com\/#organization","name":"Fineline Infomation and Technology","alternateName":"Fineline Info & Tech","url":"https:\/\/flcube.com\/","logo":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/flcube.com\/#\/schema\/logo\/image\/","url":"https:\/\/flcube.com\/wp-content\/uploads\/2024\/11\/Fineline-info-tech-scaled.jpg","contentUrl":"https:\/\/flcube.com\/wp-content\/uploads\/2024\/11\/Fineline-info-tech-scaled.jpg","width":2560,"height":1894,"caption":"Fineline Infomation and Technology"},"image":{"@id":"https:\/\/flcube.com\/#\/schema\/logo\/image\/"},"sameAs":["https:\/\/www.facebook.com\/profile.php?id=61566606313834"]},{"@type":"Person","@id":"https:\/\/flcube.com\/#\/schema\/person\/19ad11870d326204db8524d3c3c5e66a","name":"Fineline Cube","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/secure.gravatar.com\/avatar\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g","url":"https:\/\/secure.gravatar.com\/avatar\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g","caption":"Fineline Cube"},"sameAs":["https:\/\/flcube.com"],"url":"https:\/\/flcube.com\/?author=1"}]}},"jetpack_publicize_connections":[],"jetpack_featured_media_url":"","jetpack_sharing_enabled":true,"_links":{"self":[{"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts\/64570","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Fcomments&post=64570"}],"version-history":[{"count":1,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts\/64570\/revisions"}],"predecessor-version":[{"id":64754,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts\/64570\/revisions\/64754"}],"wp:attachment":[{"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Fmedia&parent=64570"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Fcategories&post=64570"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Ftags&post=64570"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}